Precision BioSciences Announces that the US Patent Office Issues Final Decisions Rejecting Claims of Four Cellectis Patents

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued Final Decisions and Right of Appeal Notices in the reexamination proceedings for U.S. Pat. Nos. 6,833252, 7,214,536, 6,610,545 (“the ‘545 patent”), and 7,309,605 (“the ‘605 patent”) that are owned by the Institut Pasteur and the Universite Pierre et Marie Curie, and licensed to Cellectis, SA (ALCLS). The ‘545 patent and the ‘605 patent were asserted against Precision in litigation filed in March 2008 by Cellectis. That litigation was subsequently stayed (or halted) by the court due to the PTO’s actions in reexamination proceedings requested by Precision BioSciences. The final decisions issued by the PTO include rejections of every patent claim that was asserted against Precision in the litigation, as well as many related claims. In total, 78 of Cellectis’ patent claims were challenged by Precision, and 77 were canceled or rejected in the final decisions from the PTO. The sole surviving claim is irrelevant to Precision’s business. The patent owners have the right to appeal the decisions on reexamination to the PTO’s Board of Patent Appeals and Interferences.

Back to news